Select Page
Responsive Centered YouTube Video
Investigation into the Delayed Reporting of a Drug Failure Study
  • Dr. McMillan discusses delayed reporting of a drug study without naming specifics. 0:01

  • Previous experience with restrictions on discussing companies leads to cautious approach. 0:38

  • Upcoming projects include a disease X book compilation and a book launch for Humming Heroes. 1:44

  • Advanced360 pre-launch sale offers significant discounts for upcoming course modules. 3:33

Delay in reporting failure of Paxlovid efficacy in treating COVID-19 raises questions about scientific community's awareness
  • Publication of Paxlovid failure delayed for almost two years after initial study showed benefit. 3:56

  • Recent study in April 2024 concluded no significant difference in efficacy between Paxlovid and placebo. 5:30

  • CDC still recommends Paxlovid despite lack of proven effectiveness against COVID-19. 6:43

  • Lack of effective antiviral treatment accepted by scientific community to stop COVID-19. 7:16

  • Question raised on why it took so long to report the failure of Paxlovid. 7:22

  • Significance of delayed publication in understanding the evolving landscape of COVID-19 treatments. 7:45

  • Challenges in reconciling conflicting study results and implications for future research and treatment strategies. 8:04

Delay in publishing negative results of Paxlovid study raises questions about timing and impact
  • Study completed in December 2021, published in February 2022, showing quick turnaround potential. 8:17

  • Another study completed in July 2022 but published in April 2024, raising concerns about the delay. 9:31

  • Significant delay of almost 2 years between study completion and publication without clear reasons. 10:33

  • Data on adverse events and lack of significant benefits from Paxlovid treatment highlighted in the study. 12:17

  • Questions raised on the impact of delayed publication on sales and public perception of the medication. 13:05

Factors contributing to the lack of efficacy of an antiviral drug in vaccinated individuals
  • Initial trial showed benefit in unvaccinated cohort but not in mixed cohort. 13:54

  • Possible impact of natural immunity in unvaccinated cohort on trial outcome. 14:51

  • Antiviral drug targets specific protease enzymes of the Coronavirus. 15:47

  • Speculation on immune failure and presence of immune-tolerant antibodies in vaccinated individuals. 16:09

  • Suggested need for longer treatment duration in vaccinated individuals due to potential immune deficiency. 17:03

  • Drug slows down viral replication process, while immune system clears infected cells. 17:41

Concerns raised about immune system failure, need for new leadership to address challenges in protecting at-risk individuals from severe disease
  • Combination of immunity and viral proteins slowing virus down 17:57

  • Issues around finance and immune failure in cohort 18:14

  • Science indicating serious challenge ahead, need to stop virus circulation 18:56

  • Main organizations promoting pharmaceutical therapies facing limitations 19:04

  • Urgent need to protect at-risk individuals from severe disease 19:42

  • Call for new leadership to address current crisis 20:00

  • Concern about big pharma taking advantage of situation, need for protection 20:22